Annales pharmaceutiques francaises最新文献

{"title":"Crystal structure, spectral characterization, photophysical properties, Hirshfeld surface analysis, and antimicrobial activity of homopiperazinium dichromate(VI).","authors":"Utkirjon Holikulov, Sonia Trabelsi, Houda Marouani, Thierry Roisnel, Omar M Al-Dossary, Abduvakhid Jumabaev, Noureddine Issaoui","doi":"10.1016/j.pharma.2025.07.010","DOIUrl":"https://doi.org/10.1016/j.pharma.2025.07.010","url":null,"abstract":"<p><p>This work presents a comprehensive study of the crystal structure, spectral properties (IR and UV-Vis), thermal behavior, and antimicrobial activity of homopiperazinium dichromate (C₅H1₄N₂)Cr₂O₇(VI). X-ray diffraction reveals that the compound crystallizes in the monoclinic space group P2₁/c, with unit cell dimensions a = 8.7275(8) Å, b = 10.5769(11) Å, and c = 14.7467(10) Å and β =122.941(4) °. The crystal packing is stabilized by intermolecular N-H···O and C-H···O hydrogen bonds, with Hirshfeld surface analysis revealing dominant O···H/H···O interactions contributing 80.5% to the overall crystal cohesion. UV-Vis absorption bands are observed at 279, 354, and 446 nm, with an estimated band gap energy of 3.019 eV, indicating high stability and moderate optical activity. Thermal analysis shows an intense endothermic fusion peak followed by continuous decomposition, leading to chromium oxide formation. Antimicrobial tests demonstrate significant inhibition activity against tested pathogens, including notable antifungal effects against Candida albicans. These results highlight the potential of this hybrid material in antimicrobial development and photochemical applications.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Synthesizing Safety Data on Novel Intravaginal Formulations: A Comprehensive Scoping Review of In vivo and In vitro Research\".","authors":"T P Athul, Anjani Seth, Vanshika Sharma, Meenakshi Pandey, R Galib, Sanjay Jachak, Tanuja Nesari, Meena S Deogade","doi":"10.1016/j.pharma.2025.07.009","DOIUrl":"https://doi.org/10.1016/j.pharma.2025.07.009","url":null,"abstract":"<p><strong>Background and objectives: </strong>Intravaginal drug delivery systems are gaining attention for their potential to treat local and systemic gynaecological conditions, offering advantages such as bypassing hepatic first-pass metabolism and improved bioavailability. However, the safety evaluation of these novel formulations remains inconsistent, with limited regulatory guidance. This scoping review aims to consolidate data from in vivo and in vitro safety studies to support the design of standardized safety protocols for future intravaginal formulations.</p><p><strong>Materials and methods: </strong>A systematic data search was conducted using PubMed and Scopus (2009-2024) data base following PRISMA-ScR guidelines. Eligible studies were included after data screening by individual reviewers. Study selection, data extraction, and charting were performed using a pre-defined protocol registered on the Open Science Framework.</p><p><strong>Results: </strong>A total of 77 studies were included, comprising 64 in vivo and 13 in vitro studies. Rabbit was the frequently used animal model, while HeLa and normal vaginal epithelial cells were predominant in cell-based assays. Key safety endpoints evaluated included vaginal irritation, systemic toxicity, cytotoxicity, and cytokine expression. A wide range of formulations was assessed, including gels, rings, suppositories, and hydrogels.</p><p><strong>Conclusions: </strong>This review highlights the need for harmonized safety assessment protocols for intravaginal formulations. By mapping current practices and models used in preclinical research, this work offers a foundation for researchers and regulators to develop more robust and standardized safety evaluation frameworks.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laggera pterodonta: Traditional uses, phytochemistry and biological activities.","authors":"Pham Van Huyen, Nguyen Thi Thu Hien, Tran Thi Ngoc Hanh, Nguyen Huu Huong Duyen, Nguyen Huu Toan Phan, Nguyen Thi Dieu Thuan","doi":"10.1016/j.pharma.2025.07.008","DOIUrl":"https://doi.org/10.1016/j.pharma.2025.07.008","url":null,"abstract":"<p><p>Laggera pterodonta is a promising medicinal plant with multiple therapeutic applications, supporting its traditional use and potential for modern drug development. With its diverse bioactive constituents such as flavonoids, terpenoids, phenolics, alkaloids, and lignans, along with antiviral activity, anti-inflammatory activity, insecticidal activity, antibacterial activity, and antifungal activity, L. pterodonta is gradually asserting its value in pharmaceutical applications. Studies have shown its effectiveness against influenza viruses, enteroviruses, and herpes simplex viruses by inhibiting viral replication and modulating immune responses. Additionally, its anti-inflammatory effects help reduce pro-inflammatory cytokines, while its antimicrobial and antifungal activities make it a promising candidate for combating drug-resistant pathogens. The plant's insecticidal properties suggest its potential use in eco-friendly pest control. The present review aims to provide an in-depth report on the traditional uses, phytochemistry, and biological activities of L. pterodonta. These knowledge provides scientists with a clear direction for effectively utilizing the plant in the search for potent and sustainable medicinal resources for public health care.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144681911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Impact of therapeutic education on knowledge, adherence, asthma control, and respiratory function in asthmatic patients: A 6-month follow-up].","authors":"Faiza Sebhi, Lydia Adjou, Rania Bazia, Djazia El Hadef, Merzak Gharnaout, Reda Djidjik","doi":"10.1016/j.pharma.2025.07.007","DOIUrl":"10.1016/j.pharma.2025.07.007","url":null,"abstract":"<p><strong>Introduction: </strong>Therapeutic patient education (TPE) is a key component in the management of asthma. This study aims to assess the impact of TPE on disease control, treatment adherence, lung function, and the frequency of hospitalizations and emergency visits.</p><p><strong>Methods: </strong>A pilot study followed by an interventional study was conducted on 47 asthmatic patients at CHU Issaad Hassani in Algiers. The participants attended TPE sessions and were evaluated at multiple time points: T0 (before TPE), T4 (4 weeks), T8 (8 weeks), T12 (12 weeks), and T24 (24 weeks).</p><p><strong>Results: </strong>The findings show a significant improvement in patients' knowledge, treatment adherence, and asthma control. A notable progression in inhaler technique (IT) was also observed. Additionally, the number of hospitalizations significantly decreased after TPE, while emergency visits showed no significant change. Regarding lung function, an improvement in the ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC) was observed in the short term (T12) but not in the long term (T24).</p><p><strong>Conclusion: </strong>These results confirm the effectiveness of TPE in improving asthma patient management. Integrating TPE into care protocols, along with regular follow-up, is essential to optimize asthma control and enhance patients' quality of life.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Implementation and evaluation of the Objectives Structured Practical Examination (OSPE) in the French pharmacy curriculum: Feedback from a first experience at the Lille Faculty of Pharmacy].","authors":"Cyrille Berlemont, Yanèle Poteaux, Anne Garat, Sébastien Zanetti, Patrick Wierre, Tony Sanctorum, Pierre Ravaux, Bertrand Décaudin, Annie Standaert","doi":"10.1016/j.pharma.2025.07.006","DOIUrl":"10.1016/j.pharma.2025.07.006","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this work is to evaluate the implementation of Objective Structured Practical Examinations (OSPE) at the Lille Faculty of Pharmacy as part of the skills assessment of 6th year pharmacy students.</p><p><strong>Method: </strong>The OSPE was designed and implemented in 2022 as a summative exam of the 1st semester of the 6th year. The stations were designed in accordance with our educational framework in the field of community pharmacy. Student performance scores were collected and analyzed using descriptive statistics. After the summative assessment, students completed an anonymous electronic survey concerning their opinion and perception on the suitability of the OSPE.</p><p><strong>Results: </strong>OSPE consisted of 8 stations, 6 of which involved standardized participants. The skills assessed included dispense medicines or health products, respond to a patient's request, patient-centered approach, interprofessional communication, apply legal practices, and administer vaccines. 105 students participated in the first edition in December 2022. The overall pass rate was 62.8%. Stations focusing on interprofessional communication and vaccine administration were more successful than those focusing on patient support (particularly in oncology). A total of 84.8% of the students found the method to be relevant, and 73.3% felt that it had enabled them to become more aware of their skills. However, 91% reported that OSPE was stressful. Students also reported that the stations on legislation and oncology patient care did not match they had seen during their training.</p><p><strong>Conclusions: </strong>The OSPE experience at the Lille Faculty of Pharmacy highlights the relevance of this tool to assess the skills of future community pharmacists. However, changes are needed to enhance the alignment between OSPE and training, and to better prepare students for this new assessment approach. This initiative is part of a broader reflection undertaken by the Faculty in anticipation of the forthcoming reform of pharmacy studies in France aimed at better addressing the evolving needs of the profession.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of cytotoxic activity properties of etoxazole towards human cancer and healthy cell lines and molecular docking studies.","authors":"İkbal Demet Nane","doi":"10.1016/j.pharma.2025.07.001","DOIUrl":"10.1016/j.pharma.2025.07.001","url":null,"abstract":"<p><p>The effect of etoxazole on cancer cells was evaluated in vitro using different cell lines. In this context, its cytotoxic activity on breast (MCF-7), liver (HepG2), colon (DLD-1) and lung (A549) cancer cell lines was investigated. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method was used to determine the effects on cell viability. Tests were also performed on a healthy human embryonic kidney cell line (HEK-293T) to evaluate the selectivity of the compound. The results revealed that etoxazole showed varying degrees of antiproliferative activity in cancer cell lines. In particular, it showed the most potent inhibition effect with an IC₅₀ value of 33.18μM in HepG2 cell line. In contrast, in the A549 cell line, the IC₅₀ value was measured as 91.38μM, indicating that the compound had a lower cytotoxic effect in lung cancer cells. Etoxazole, which exhibited a more pronounced effect against liver cancer cells, showed moderate cytotoxicity in other cell lines. Moreover, the IC₅₀ value in healthy HEK-293T cells was found to be 1628.0μM, which demonstrates that etoxazole has a high selectivity index and low toxicity towards normal cells. On the other hand, evaluations in the healthy HEK-293T cell line revealed that etoxazole has a selective effect. The IC₅₀ value in healthy cells was relatively high, suggesting that the compound may exhibit a specific cytotoxic activity against cancer cells. In general, etoxazole was found to have varying levels of cytotoxic activity in different cancer cell lines. The effect of the compound varied depending on the cell type and it was observed that it exhibited a more pronounced antiproliferative activity especially in liver cancer cells. These results indicate that etoxazole may be a promising candidate for hepatocellular carcinoma treatment. Furthermore, molecular docking simulations were conducted to evaluate the binding mode and affinity of the etoxazole ligand against the Kinase Insert Domain Receptor (PDB ID: 3WZE). The docking results indicated that etoxazole exhibited a binding energy of -8.6kcal/mol and formed stable interactions within the active site, suggesting a high inhibitory potential. In particular, key stabilizing interactions were identified, including hydrogen bonds with ASP183 and a halogen bond with GLU72, further supporting the molecular affinity. These findings suggest that etoxazole may be the subject of further research as a potential anticancer agent.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design, development and evaluation of curcumin (Curcuma longa) encapsulated phospholipid nanocarrier to enhance solubility and improve efficacy in MCF-7 cell line by Quality by Design.","authors":"Vaibhav Bhadange, Supriya Jogdand, Ankita Kawtikwar, Pravin Kawtikwar","doi":"10.1016/j.pharma.2025.07.004","DOIUrl":"10.1016/j.pharma.2025.07.004","url":null,"abstract":"<p><p>Lipid-based excipients are increasingly used to enhance the stability of innovative drug delivery systems. Phospoholipid nanocarriers, a botanical formulation, are used to build lipophilic molecular complexes, improving stability, absorption, and bioavailability. Turmeric (Curcuma longa) contains curcumin, which has poor bioavailability due to its solubility and wettability. Hence, the study was designed to enhance the solubility of curcumin by phospholipid complexation. The curcumin-encapsulated phospholipid nanocarriers (Ccm-PNs) were developed by solvent evaporation method, and the formula was optimized using a Box-Behnekn design based on QbD. Physicochemical properties and functional characterization were done by accessing particle size, entrapment efficiency, in vitro drug release. The adenocarcinoma breast cell line (MCF-7) was used for cytotoxicity investigation of Ccm-PNs. It showed lower particle size and stable zeta potential values, and their compatibility with excipients was confirmed through DSC and FTIR studies. They also demonstrated higher entrapment and in vitro drug release over 48hours. The cytotoxicity study showed improved efficacy than pure curcumin solution. In conclusion, overall results show that phospholipid nanocarriers have the ability to enhance therapeutic efficacy and bioavailability.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Incompatibility of injectable drugs in neonatal intensive care: From assessment to implementation of a preventive tool].","authors":"Marie Guedon, Catherine Mennesson, Baptiste Fulbert, Elise D'huart, Laura Menvielle, Elodie Tisserand, Dominique Hettler","doi":"10.1016/j.pharma.2025.07.002","DOIUrl":"10.1016/j.pharma.2025.07.002","url":null,"abstract":"<p><strong>Introduction: </strong>Complex administration patterns in neonatal intensive care lead to the mixing of several active ingredients on the same route. The aim of this study was to assess the frequency of these concomitant administrations and their physico-chemical compatibility, and then to establish a specific compatibility table.</p><p><strong>Material and methods: </strong>A prospective, observational, single-center study was carried out in a neonatal intensive care unit between February 15 and April 2, 2024. Data (patients, approaches, parenteral nutrition, injectable drugs [dose, dilution, administration methods]) were collected from computerized prescriptions and observation of connections at the patient's bed. Compatibilities were assessed using Stabilis® and the Handbook of Injectable Drugs®.</p><p><strong>Results: </strong>Forty-nine prescriptions containing 385 Y combinations were included: 36% were compatible, 3% incompatible and 46% not studied. A compatibility table was created, including 24 of the most commonly prescribed molecules (anti-infectives and nervous system drugs specifically).</p><p><strong>Discussion and conclusion: </strong>Y-combinations appear inevitable in patient management. Although few incompatible associations have been observed, the absence of data for many molecules should lead to increased vigilance. The creation of a specific compatibility table would appear to be a tool that would reduce the risk of incompatibility. An evaluation of this tool should be envisaged, as well as an extension of the project to the establishment's various pediatric departments.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncology pharmacy practice: Key insights, challenges, and perspectives - A position paper from the French Society for Oncology Pharmacy (SFPO).","authors":"Florence Ranchon, Florian Slimano, Isabelle Borget, Mathieu Boulin, Christophe Bardin, Pierre Coliat, Nicolas Cormier, Catherine Devys, Raphaelle Fanciullino, Muriel Paul, Florent Puisset, Catherine Rioufol, Lionel Tortolano, Jean-François Tournamille, Jean Vigneron, Régine Chevrier, Bertrand Pourroy, Jean-Louis Cazin","doi":"10.1016/j.pharma.2025.07.005","DOIUrl":"10.1016/j.pharma.2025.07.005","url":null,"abstract":"<p><p>The role of hospital oncology pharmacists (HOP) in the care of cancer patients has evolved considerably. This evidence led the experts of the French Society for Oncology Pharmacy (SFPO) to write a position paper. The first part presents the key insights of oncology pharmacy services (technology aspects of anticancer drug preparation and clinical pharmacy services), training of HOPs and research activities (clinical trials, research in oncology pharmacy). The second part of this position paper refers to the challenges and perspectives of E-health and artificial intelligence, precision medicine, access to innovation, and environmental issues.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in FDA drug approvals: 2021-2024 insights & innovations.","authors":"Geet Raut, Sanjay Sharma","doi":"10.1016/j.pharma.2025.06.004","DOIUrl":"10.1016/j.pharma.2025.06.004","url":null,"abstract":"<p><p>From 2021-2024, the U.S. Food and Drug Administration (FDA) approved novel drugs, advancing treatments in neurology, oncology, infectious diseases and rare disorders. This review analyzes approval trends, highlighting the targeted diseases and biologics, the rise of expedited pathways and focus on unmet medical needs. These examines key therapeutic areas the approval trends of different categories. The analysis draws on data from the FDA's Center for Drug Evaluation and Research (CDER) to provide insights into novel drug indication, regulatory innovations and their implications to healthcare. The review analyzes trends in drug approvals.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}